Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Zhaoyu XueDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0001-7288-8780
Lihuai QinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, New York, USA.ORCID 0000-0001-5795-5703
Hongwen XuanDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0002-5820-6250
Kaixiu LuoMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, New York, USA.ORCID 0000-0002-7910-7454
Mengying HuangDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0002-9719-4619
Ling XieDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yangzhou SuDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0009-0002-7820-7100
Longxia XuDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Josiah HarshDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0009-0000-3989-1697
Brandon DaleMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, New York, USA.
Xiaobing ShiDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0001-5242-8189
Xian ChenDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
H Ümit KaniskanMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, New York, USA.ORCID 0000-0001-5327-832X
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, New York, USA.ORCID 0000-0002-2387-3862
Hong WenDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0001-8739-4572
Funding
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged LeukemiasR01CA260666 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN, WEN, HONG · 2021 to 2025
$2.5M
Discovery of small molecules targeting the histone acetylation reader ENLR01CA255506 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI WEN, HONG · 2021 to 2024
$1.7M
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7M
Molecular mechanisms of CIB1 signalingR01GM133107 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, XIAN · 2019 to 2020
$617k
An AVANCE NEO 400 MHz NMR Spectrometer for Chemical Biology and Drug DiscoveryS10OD028504 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2020 to 2020
$599k
An AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical BiologyS10OD025132 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2019 to 2019
$535k
Deciphering the non-canonical function of the histone methyltransferase G9a in the etiology of ADR21AG071229 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, XIAN · 2021 to 2022
$428k
Novel therapeutic intervention of early-stage T1DR41DK133051 · NIDDK · TRANSCHROMIX, LLC. · PI CHEN, XIAN · 2023 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression. · full record | Socratic